The MPTP model is commonly used to study PD pathogenesis. ATH has used it in several preclinical studies, including the primate study. As you may remember, the MPTP model was invented after a drug addict had caused his PD symptoms by injecting MPTP into his veins.
Unfortunately, not a very easy paper for me, but energy production in mitochondria is hampered.Deficient AMPK-SENP1-Sirt3 signaling impairs mitochondrial complex I function in Parkinson's disease model
Xiaoyu Sun # 1 2, Jianyi Shen # 3, Yimei Shu 1, Tianshi Wang 4, Lu He 1, Ruinan Shen 1, Yifan Zhou 1, Jinke Cheng 5, Suzhen Lin 6, Jianqing Ding 7AffiliationsPMCID: PMC12211261 DOI: 10.1186/s40035-025-00489-2
- PMID: 40597361
Abstract
Background: Epidemiological studies have revealed increased Parkinson's disease (PD) risk among individuals exposed to pesticides like 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MPTP is frequently used to induce PD-like symptoms in research models by disrupting mitochondrial complex I (CI) function and causing dopaminergic neuronal loss in the nigrostriatal region. However, the pathway(s) through which MPTP impairs mitochondrial CI function remain to be elucidated. In this study, we aim to identify the molecular mechanisms through which MPTP modulates CI function and define the specific subunits of mitochondrial CI affected by MPTP.
Methods: Male mice encompassing either wild-type Sirt3 or Sirt3 K223R de-SUMOylation mutation, were intraperitoneally injected with either MPTP or saline. In vitro experiments were conducted using the SH-SY5Y cell line with or without the Sirt3 de-SUMOylation mutation. Movement performance, mitochondrial function, and protein acetylation were evaluated.
Results: MPTP exposure, both in vitro and in vivo, disrupted the AMPK-SENP1-Sirt3 axis, leading to impairment of mitochondrial function. Specifically, MPTP suppressed activation of AMPK, impeding the entry of SENP1 into the mitochondria. The lack of mitochondrial SENP1 resulted in increased levels of SUMOylated Sirt3, which inhibited its deacetylase activity. This led to a significant increase in the acetylation of CI subunits NDUFS3 and NDUFA5, which resulted in reduced CI activity and inhibition of mitochondrial function, and eventually dopaminergic neuronal death. In this pathway, sustained deSUMOylation mutation of Sirt3 (K223R in mice, K288R in humans) mitigated the impact of MPTP on mitochondrial dysregulation, as well as dopaminergic neuronal death and behavioral deficits.
Conclusion: The disordered AMPK-SENP1-Sirt3 pathway plays a crucial role in the MPTP-induced CI dysfunction and PD-like phenotype, which provide valuable insights into the mechanisms of PD pathogenesis.
Paper is free: https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-025-00489-2
- Forums
- ASX - By Stock
- ATH
- Explaining PD animalmodel on mitochondrion level used by ATH
ATH
alterity therapeutics limited
Add to My Watchlist
15.4%
!
1.5¢

Explaining PD animalmodel on mitochondrion level used by ATH
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.5¢ |
Change
0.002(15.4%) |
Mkt cap ! $138.1M |
Open | High | Low | Value | Volume |
1.4¢ | 1.5¢ | 1.4¢ | $70.41K | 5.037M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 95000 | 1.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.5¢ | 21150934 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 70000 | 0.014 |
40 | 23014925 | 0.013 |
30 | 15509733 | 0.012 |
17 | 12434327 | 0.011 |
33 | 15163355 | 0.010 |
Price($) | Vol. | No. |
---|---|---|
0.015 | 21150934 | 14 |
0.016 | 3096642 | 8 |
0.017 | 7321224 | 9 |
0.018 | 12443520 | 20 |
0.019 | 10047176 | 10 |
Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |